Establishment of an animal model of immune‐related adverse events induced by immune checkpoint inhibitors

Documenti analoghi

• Incidence and risk factors of immune‐related adverse events induced by immune checkpoint inhibitors among older adults with non‐small cell lung cancer
  di: Yiran Rong, et al.
  Pubblicazione: (2024)
• Cardiovascular adverse events associated with immune checkpoint inhibitors: A retrospective multicenter cohort study
  di: Yi Zheng, et al.
  Pubblicazione: (2024)
• Predictive capacity of immune‐related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma
  di: Angela E. Alnemri, et al.
  Pubblicazione: (2024)
• Impact of immune‐related adverse events on survival outcomes in extensive‐stage small cell lung cancer patients treated with immune checkpoint inhibitors
  di: Tadashi Nishimura, et al.
  Pubblicazione: (2024)
• Tissue‐resident memory T cells in immunotherapy and immune‐related adverse events by immune checkpoint inhibitor
  di: Hao Xiong, et al.
  Pubblicazione: (2024)